Altria Q3 2026 Earnings: Pricing Supports EPS as Cigarette Volumes Fall

Altria Group (NYSE: MO) reported Q3 2026 net revenues of $6.132 billion, up 1.0% year over year, while reported diluted EPS increased 7.1% to $1.51 and adjusted diluted EPS rose 4.8% to $1.52. Pricing supported smokeable-products profit despite declining cigarette shipments, whereas lower volumes and higher costs compressed oral-tobacco profitability. Altria also raised its full-year adjusted EPS guidance and expanded its share repurchase authorization.

Core Earnings Data

Revenue net of excise taxes grew faster than headline net revenue, rising 3.6% to $5.441 billion. The company attributed the EPS increases primarily to higher operating companies income and higher earnings from its investment in Anheuser-Busch InBev.

Adjusted EPS growth was lower than reported EPS growth after excluding special items. Those adjustments included litigation costs, intangible-asset amortization, tax items and gains related to the ABI investment.

The prior-year revenue figures are approximate values calculated from the reported current-period amounts and growth rates.

Business and Segment Performance

Smokeable products remained the primary earnings driver. Higher pricing and refunds of taxes and duties on imported cigarettes more than offset lower shipment volume, increased promotions, an unfavorable shift toward discount products and higher manufacturing costs. Adjusted operating companies income, or OCI, increased 3.9%, and the adjusted margin edged up to 64.5%.

Oral tobacco moved in the opposite direction. Revenue was nearly unchanged, but adjusted OCI fell 3.7% and the adjusted margin contracted 2.8 percentage points as lower shipments, higher promotional spending and increased costs outweighed pricing.

Adjusted OCI margins are calculated using segment revenue net of excise taxes.

Cigarette Pricing Offset Lower Volume

After adjusting for trade inventory movements, Altria estimated that its domestic cigarette shipments declined about 4%, compared with an estimated 5% contraction for the overall industry. That relative performance helped total company cigarette retail share increase 0.3 percentage points to 45.7%.

The mix continued to shift toward lower-priced products. Marlboro shipments fell 6.4% and its share of the total cigarette category declined 1.0 percentage point to 39.5%, even as its premium-segment share increased 0.3 percentage points to 60.0%. Discount-brand shipments rose 40.5%, while the industry’s discount retail share increased 2.0 percentage points to 34.1%. Altria attributed the broader discount shift to continued pressure on adult smokers’ discretionary income.

on! Grew, but Oral-Tobacco Share Remained Under Pressure

The oral segment’s total shipments declined even though on! volume increased 13.3% to 47.8 million cans. Copenhagen and Skoal shipments fell 10.1% and 12.6%, respectively, showing that pouch growth did not fully offset weakness in traditional moist smokeless tobacco.

Nicotine pouches expanded to 61.2% of the oral-tobacco category, up 5.8 percentage points. However, on!’s share of the pouch category decreased 1.3 percentage points to 13.5%, indicating that category growth was outpacing the brand’s gains. Helix expanded on! PLUS with additional flavors across 6-, 9- and 12-milligram strengths and plans another flavor introduction at select retailers in the fourth quarter.

Capital Returns

Altria repurchased 5.9 million shares during the quarter at an average price of $68.52, spending $400 million. It also paid $1.7 billion in dividends.

The board authorized a $1 billion expansion of the existing repurchase program, which now expires on December 31, 2027. Separately, the quarterly dividend was increased 4.7% in August, bringing the annualized rate to $4.44 per share. These actions describe capital allocation decisions and do not, by themselves, indicate management’s assessment of the stock’s valuation.

2026 Earnings Guidance

Altria raised its full-year adjusted diluted EPS outlook, citing its performance through the first nine months and confidence in its full-year plan. The release did not provide the previous guidance range, so the size of the increase cannot be calculated from the supplied information.

The outlook assumes moderated e-vapor industry growth will affect combustible and e-vapor volumes, NJOY ACE will not return to the market in 2026 and macroeconomic uncertainty will continue to affect adult nicotine consumers. It also incorporates investments in contract manufacturing and Altria’s long-term strategy, along with reinvestment of expected savings from the Optimize & Accelerate initiative.

Recent Insider Transactions

The six-month insider summary categorized 65,858 shares across 10 purchase transactions and 7,790 shares across two sales, producing net purchases of 58,068 shares. The underlying list shows that multiple purchase entries were zero-price stock awards rather than open-market cash purchases.

The two most recent reported sales occurred on May 26, 2026, with a combined reported value of approximately $563,436. The latest 10 records also included eight direct stock-award grants at $0 on May 14.

These transactions provide a record of insider activity but do not establish insiders’ views on Altria’s future performance.

Risks Investors Should Monitor

• Persistent cigarette contraction: Adjusted domestic cigarette shipments declined about 4%, and continued volume erosion could make earnings increasingly dependent on pricing.
• Migration toward discount cigarettes: Industry discount share rose as consumer purchasing power remained pressured. A sustained mix shift could reduce the benefit of premium-brand pricing.
• Oral-tobacco margin pressure: The segment’s adjusted margin fell 2.8 percentage points as lower shipments, promotions and higher costs outweighed pricing.
• Weak share performance within nicotine pouches: on! shipments grew, but its share of the expanding pouch category declined, suggesting intensified competitive pressure.
• E-vapor limitations and investment spending: Guidance assumes NJOY ACE remains off the market in 2026 while Altria continues spending on contract manufacturing, cost initiatives and its smoke-free strategy.

Summary

Altria’s Q3 2026 earnings showed that pricing and tax refunds can still offset declining cigarette volumes and support smokeable-products profit. The main pressure came from oral tobacco, where on! growth did not prevent lower total shipments or margin contraction. The raised adjusted EPS outlook signals greater confidence in the full-year plan, while cigarette mix, nicotine-pouch share and the returns from ongoing smoke-free investments remain the key operating issues to track.